Source: @medlabAUS Facebook
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medlab Clinical (MDC) has been awarded research and development approval from AusIndustry for a program to develop its cannabis-based pain treatment drug
  • The company was granted an “advanced and overseas finding” for the development of NanaBis as part of the Australian Federal Government’s R&D Tax Incentive program
  • Medlab says the approval will significantly extend the company’s cash runway, as well as its overall financial performance
  • The investment is said to de-risk the financial commitment associated with the last stages of its development
  • Medlab Clinical was up 3.23 per cent, trading at 16 cents at 1:50 pm AEDT

Medlab Clinical (MDC) has been awarded research and development approval from AusIndustry for a program to develop its product NanaBis.

NanaBis is Medlab’s patented lead drug candidate, developed for cancer bone pain as a viable alternative to opioids. The company said its data suggests the product may be equally effective in non-cancer neuropathic pain.

The company was granted an “advanced and overseas finding” for the development of the cannabis-based pain treatment drug by a division of the Australian Government’s Department of Industry, Science, Energy and Resources as part of the Australian Federal Government’s R&D Tax Incentive program.

Medlab says the approval will significantly extend the company’s cash runway, as well as the overall financial performance.

The total expenditure for NanaBis development in Australia and overseas for the three-year period is expected to sit at more than $26.9 million.  

Medlab CEO Dr Sean Hall said the investment de-risks the financial commitment associated with the last stages of its development.

“This outcome will directly support the company’s go-forward program for NanaBis with a 43.5 per cent cash rebate expected on the overseas expenditure in the Advanced Overseas Finding,” said Dr Hall.

“The approximate $27 million expenditure is allotted over an anticipated three years with the outcome taking 2023 into account.”

Medlab Clinical was up 3.23 per cent, trading at 16 cents at 1:50 pm AEDT.

MDC by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…